Crossmark

Comparison of the procedure time differences between hybrid endoscopic submucosal dissection and conventional endoscopic submucosal dissection in patients with early gastric neoplasms: a study protocol for a multi-center randomized controlled trial (Hybrid-G trial)

Crossref DOI link: https://doi.org/10.1186/s13063-022-06099-x

Published Online: 2022-02-21

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Esaki, Mitsuru

Ihara, Eikichi https://orcid.org/0000-0002-7070-6610
Fujii, Hiroyuki

Sumida, Yorinobu

Haraguchi, Kazuhiro

Takahashi, Shunsuke

Iwasa, Tsutomu

Nakano, Kayoko

Wada, Masafumi

Somada, Shinichi

Minoda, Yosuke

Ogino, Haruei

Tagawa, Koshiro

Ogawa, Yoshihiro
License Information

Text and Data Mining valid from 2022-02-21

Version of Record valid from 2022-02-21
More Information

Article History

Received: 1 April 2021

Accepted: 10 February 2022

First Online: 21 February 2022

Declarations

:

: This trial has been approved by the Institutional Review Board (IRB) of Kyusyu University for clinical trials (IRB No. 20202005; July 28, 2020), as well as by the IRBs of each participating institution. This trial has been registered at UMIN-CRT (ID: 000041244; 29 July 2020). The trial protocol (vol. 1.0; June 1, 2020) was designed in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines. Informed consent will be obtained from all study participants.

: Not applicable.

: E.I. has received lecture honoraria from Takeda Pharmaceutical Co., Ltd. E.I. belongs to an endowed course supported by the following companies: Ono Pharmaceutical Co., Ltd.; Miyarisan Pharmaceutical Co. Ltd.; Sanwa Kagaku Kenkyusho Co., Ltd.; Otsuka Pharmaceutical Factory, Inc.; Fujifilm Medical Co., Ltd.; Terumo Corporation; Fancl International, Inc.; and Ohga Pharmacy. The other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below